VolitionRX’ (VNRX) CEO Cameron Reynolds on Q2 2017 Results – Earnings Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited’s Second Quarter 2017 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, Thursday, August 10, 2017.
I’d now like to turn the conference over to Mr. Scott Powell, Executive Vice President of VolitionRx Limited. Please go ahead, sir.
Thank you, and welcome everyone to today’s earnings conference call for VolitionRx Limited. This call will cover Volition’s financial and operating results for the second quarter of 2017, which ended June 30, 2017, along with a discussion of our recent activities and key upcoming 2017 milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session. Also on our call today are Mr. Cameron Reynolds, President and Chief Executive Officer; and Mr. David Vanston, Chief Financial Officer.
Before we begin, I’d like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us.
Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements.
We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call.
I’d now like to turn the call over to our President and Chief Executive Officer, Mr. Cameron Reynolds, who will discuss our second quarter 2017 financial results and our clinical and operational objectives for the remainder of 2017. Cameron?
Thank you, Scott, and thank you everyone for joining Volition’s second quarter 2017 earnings conference call. I’d like to thank all of you again for taking an interest in Volition at this important time for us.
I’m delighted with the progress we are making on many fronts. As I’ve always said, our team is extremely important to us. We have welcomed some key hires into the business this year as our team continues to grow stronger. In April, we named David Vanston as our Chief Financial Officer. David is a very dynamic and experienced new hire, who will work with us to implement and comply with the requirements under the Sarbanes-Oxley Act of 2002, as well as to help us transition from a research to revenue company. He joins me on the call today. We’ve also added several other important members to our research and development team and to our marketing team as we continue to develop new products and market them.
In April, we celebrated the grand opening of our new research and development facility based in the Wallonia region of Belgium. This was a giant step forward in terms of our capacity to run both large clinical trials, and also to expand our efforts into other cancers; notably pancreatic, lung and prostate.